CVS Health (CVS) Q2 2026 Earnings Report

The call conveyed strong operational and financial momentum across segments with material upside: double-digit growth in operating income, raised EPS guidance, improved cash flow outlook, specialty leadership, and early tangible AI-driven efficiencies. Offsetting these positives are notable industry-specific headwinds—most prominently near-term 340B pressures, anticipated Caremark membership declines in 2027, ongoing reimbursement and regulatory pressures, and some timing-related pull-forwards. Management emphasized disciplined execution, balance sheet improvement and a multi-year growth outlook (mid-teens EPS CAGR through 2028), while acknowledging and preparing for specific near-term headwinds.

CVS raised its full‑year 2026 outlook, increasing adjusted EPS guidance to $7.90–$8.10 (up $0.60, ~+8%), raising expected cash flow from operations to at least $11.5B (up ~$2B), and targeting total revenues of at least $414B; enterprise adjusted operating income is now expected to be $16.58–$16.92B, Health Care Benefits adjusted operating income $5.03–$5.37B (up >$1B), with an expected MBR of 89.75% ±25 bps, Pharmacy & Consumer Wellness adjusted operating income at least $6.4B (up $220M) and Health Services outlook reiterated; management noted Q2 results of $5.2B adjusted operating income and $2.58 adjusted EPS, YTD cash flow from operations of ~$10.6B, parent cash of ~$2.7B and leverage of ~3.5x, said no share repurchases are assumed in the current outlook, expects second‑half EPS weighted to Q3, anticipates the Q1–Q4 MBR increase in Health Care Benefits to be slightly above 950 bps (adjusted for prior‑year development), reiterated a mid‑teens adjusted EPS CAGR for 2025–2028, and provided preliminary 2027 context implying a reasonable floor of at least $8.44 (≈13% growth off a $7.46 adjusted baseline, excluding prior‑year development and individual‑exchange items).